| 摘要 |
The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R<1 >is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC1-C3alkyl; R<2 >is hydrogen or C1-C6alkyl; L is a three atom linkage selected from -CH2-X-CH2- and -CH2-CH2-X- where the right hand side of the linkage is attached to R<3 >and where X is oxygen, sulfur or methylene; R<3 >is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC1-C6alkyl, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkylthio, haloC1-C6alkylthio and nitrile; and R<4 >and R<5 >are either both hydrogen, or one of R<4 >and R<5 >is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.
|
